Phase 2 Study of DKN-01 in Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

188

Participants

Timeline

Start Date

August 30, 2022

Primary Completion Date

July 10, 2025

Study Completion Date

July 10, 2025

Conditions
Colorectal CancerColorectal AdenocarcinomaColo-rectal CancerColorectal Cancer Metastatic
Interventions
DRUG

DKN-01

30 minute IV infusion (400mg) every two weeks with an additional loading dose in the first cycle of treatment

DRUG

FOLFIRI

90-min IV infusion of irinotecan, leucovorin, and fluorouracil followed by a continuous 46-hour infusion of fluorouracil every two weeks

DRUG

Bevacizumab

90-min IV infusion (5mg)

DRUG

FOLFOX

2 hour IV infusion of oxaliplatin, folinic acid, and fluorouracil followed by a continuous 46-hour infusion of fluorouracil every two weeks

Trial Locations (40)

10016

New York University, New York

10021

Cornell University, New York

10029

Mount Sinai Medical Center - New York, New York

10601

White Plains Hospital, White Plains

11020

Northwell Health, Lake Success

20817

Center for Cancer and Blood Disorders, Bethesda

27157

Wake Forest University, Winston-Salem

27710

Duke University Medical Center, Durham

28806

Messino Cancer Centers, Asheville

29605

Prisma Health Cancer Institute - Faris, Greenville

32003

Florida Cancer Specialists & Research Institute, Fleming Island

32605

Florida Cancer Specialists & Research Institute, Gainesville

33176

Miami Cancer Institute, Miami

33414

Florida Cancer Specialists & Research Institute, Wellington

33909

Florida Cancer Specialists & Research Institute (FCS), Cape Coral

37203

SCRI Oncology Partners, Nashville

Tennessee Oncology, Nashville

37404

Tennessee Oncology, Chattanooga

53792

University of Wisconsin Hospital and Clinics, Madison

57104

Sanford Cancer Center, Sioux Falls

65807

Oncology Hematology Associates - Springfield, Springfield

70809

Hematology Oncology Clinic, Baton Rouge

85719

The University of Arizona Cancer Center, Tucson

90404

UCLA, Los Angeles

98405

MultiCare Tacoma General Hospital, Tacoma

Unknown

Universitaetsklinikum Hamburg-Eppendorf (UKE) - Universitaeres Cancer Center Hamburg (UCCH), Hamburg

Universitaetsklinikum Heidelberg (UKHD) - Nationales Centrum fuer Tumorerkrankungen Heidelberg (NCT), Heidelberg

SLK-Kliniken Heilbronn GmbH - Klinikum am Gesundbrunnen - Klinik fuer Innere Medizin III, Heilbronn

Gemeinschaftspraxis fuer Haematologie und Onkologie - Magdeburg, Magdeburg

Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz

Dong-A University Medical Center, Busan

Kyungpook National University Chilgok Hospital, Daegu

Gachon University Gil Medical Center, Incheon

Inha University Hospital, Incheon

CHA University - Bundang CHA General Hospital, Seongnam-si

Seoul National University Bundang Hospital, Seongnam-si

Asan Medical Center, Seoul

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

The Catholic University of Korea - St. Vincent's Hospital, Suwon

Sponsors
All Listed Sponsors
lead

Leap Therapeutics, Inc.

INDUSTRY

NCT05480306 - Phase 2 Study of DKN-01 in Colorectal Cancer | Biotech Hunter | Biotech Hunter